ICON Government and Public Health Solutions

Early phase clinical research is key to refining the safety profile of new drugs and proof of concept, expanding on the data gathered in preclinical studies. Ensuring participant safety requires strategic planning at multiple levels, from protocol and dose escalation to personnel training. ICON is continuously implementing proactive participant safety measures to effectively mitigate risks in early phase studies, with regular safety drills being performed by both clinic and hospital staff to ensure highly coordinated response and execution. We have also introduced the Modified Early Warning Score (MEWS) - this is designed to identify disturbances in vital parameters and prevent further serious risk to the trial participant. Read our blog to find out more. https://ow.ly/eG6x50StFvZ #earlyphase

ICON conducted a multinational biosimilar phase 1 study for multiple sclerosis (MS). This trial was performed under high regulatory scrutiny and challenging pandemic conditions, with increased dosing targets requiring additional site activation. ICON’s early phase experience, bioanalytical capabilities, volunteer recruitment processes and site activation strategies delivered the trial successfully within the sponsor’s tight timeframe. Read more here. https://ow.ly/wTbW50Sq1T8 #earlyphase #biosimilars

AI has become a transformative tool in many areas of drug development including better management of postmarketing requirements. Learn how ICON’s AI solution Cassandra is up to 99% accurate when predicting the need for postmarketing studies. https://ow.ly/JxvO50SbtMk

We are proud to announce that our Creative & Digital Services and Global Medical Communications teams are gold Viddy winners for their work on a promotional video in the Non-Broadcast Marketing category. See it here: https://ow.ly/YKuG50Se5N8 #ViddyAwards

For a decade, healthcare providers have tried to deliver digital products comparable to consumer ones. How can they make simpler to use and safer products? Our experts examine the challenges. https://ow.ly/vXN450Sbtny

For over 30 years, ICON’s dedicated Government and Public Health Solutions team have been working hand-in-hand with US Federal agencies, leading global non-government organisations and multi-national public health organisations to deliver clinical trials that develop treatments and vaccines. Learn more: https://ow.ly/L3Ay50RlWjw #HumanlyPossible #WorldImmunisationWeek

Peter Schueler shares findings from a recent report from the International Traumatic Brain Injury Research Initiative in this article in NR Times. A useful read in Brain Injury Awareness Month. https://ow.ly/vK9U50QRe4r #BrainInjuryAwarenessMonth #TBIHope

Join ICON’s Dinah Knotts and Dr. Costanza Evangelio for an interactive roundtable discussion on the ‘unique considerations for conducting pediatric #vaccine trials’. Learn more on April 2,11:40 am and 12:30pm https://ow.ly/JzYo50QVlFG

In a shifting landscape, it can be difficult to pinpoint the greatest opportunities in obesity drug and device research and development. Explore the roles of multi-indicational efficacy and research, GLP-1 receptor agonists, and other trends and opportunities in the Q&A. https://ow.ly/pJ6Z50QU0ma

Explore the convergence of big data and artificial intelligence in optimising clinical trial success. Don't miss out on this insightful read. https://ow.ly/4cjC50QQkxj #ArtificialIntelligence #ClinicalResearch #Innovation